research chemical is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-06-03. Numbers and descriptions here follow the published literature rather than marketing material.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typical for research-grade material |
| Solubility | Soluble in DMSO and ethanol; low aqueous solubility | Organic stock solutions are common |
| Typical storage temperature | -20 °C or lower | Protect from light and moisture |
| Common analytical method | LC-MS/MS | Used for detection and confirmation |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal name |
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Abdel Fattah al-Burhan Abdelrahman al-Burhan (born 11 July 1960) is a Sudanese military officer who has been the leader of Sudan since 2019. Following the Sudanese Revolution in April 2019, he was handed control of the military junta, the Transitional Military Council, a day after it was formed, due to protesters' dissatisfaction with the establishment ties of initial leader Ahmed Awad Ibn Auf. He served as chairman of the TMC until a draft constitutional declaration signed with civilians went into effect on 17 August and a collective head of state Transitional Sovereignty Council was formed on 21 August, also to be initially headed by al-Burhan. The 2020 Juba Agreement allowed al-Burhan to continue to lead the Sovereignty Council for another 20 months, rather than stepping down as planned in February 2021. Al-Burhan seized power in a coup d'état in October 2021, dissolved the Sovereignty Council, and reconstituted it the following month with new membership, keeping himself as chairman. He was formerly the General Inspector of the Sudanese Armed Forces (SAF). He is leading the SAF against the Rapid Support Forces (RSF) in the ongoing Sudanese civil war. Al-Burhan survived an assassination attempt in July 2024.
== Description == The fruiting body is varying in size, and can be 5–30 centimetres (2–12 in) tall and 4–20 cm (1+1⁄2–8 in). Immatures have been described to be oblong, somewhat resembling the shape of a rugby ball. There is some variation in coloration, and mature Pisolithus Arhizus feature a shiny gray/brown shell with darker and lighter/whitish/yellowish patches depending on the specimen. As it ages, the fungus can develop a rudimentary stipe or stem, although not all will do this. It also tends to open up, exposing "cracks and fissures, and eventually breaking up to expose the interior." This outer peridium is roughly 1mm thick and within it can be found a mass of pea-sized "pseudoperidioles" which are structures that contain and produce spores, and are fixed in a dark gel. As a reproductive strategy, P.arhizus will release spores to the wind as the peridium turns dry and crumbly/powdery with time. The fungus has non-ornamental spores that are described as "khaki" or "cinnamon" brown, and measure roughly 5-8µm in size.
Only a year after Röntgen's discovery of X-rays, the American engineer Wolfram Fuchs (1896) gave what is probably the first protection advice, but it was not until 1925 that the first International Congress of Radiology (ICR) was held and considered establishing international protection standards. The effects of radiation on genes, including the effect of cancer risk, were recognized much later. In 1927, Hermann Joseph Muller published research showing genetic effects and, in 1946, was awarded the Nobel Prize in Physiology or Medicine for his findings. The second ICR was held in Stockholm in 1928 and proposed the adoption of the röntgen unit, and the International X-ray and Radium Protection Committee (IXRPC) was formed. Rolf Sievert was named chairman, but a driving force was George Kaye of the British National Physical Laboratory. The committee met in 1931, 1934, and 1937. After World War II, the increased range and quantity of radioactive substances being handled as a result of military and civil nuclear programs led to large groups of occupational workers and the public being potentially exposed to harmful levels of ionising radiation. This was considered at the first post-war ICR convened in London in 1950, when the present International Commission on Radiological Protection (ICRP) was born. Since then the ICRP has developed the present international system of radiation protection, covering all aspects of radiation hazards.
Ag+O2− + H2C=CH2 → (CH2CH2)O + AgO The resulting silver oxide then oxidizes ethylene or ethylene oxide to CO2 and water. This reaction replenishes the silver catalyst. Thus the overall reaction is expressed as
In 2008, she presented the Proms season on BBC Two; has also presented The Culture Show, BBC Young Musician of the Year and The Review Show; For Sky Arts, hosted programmes on Sky Arts 2; also presented Aida from Royal Albert Hall (March 2012) for The Rosenblatt Recitals; was named Music Broadcaster of the Year, winning the Silver Prize at the Sony Awards; has presented global opera broadcasts for Royal Opera, London, and hosted broadcasts of the Royal Shakespeare Company; in 2021, appointed Head of Arts and Classical Music TV. Matthew Kneale, writer (Jewish mother) Matthew Kramer (born 9 June 1959) author and editor of over twenty scholarly texts; philosopher and signatory of the Euston Manifesto; currently Professor of Legal and Political Philosophy at the University of Cambridge and a Fellow of Churchill College, Cambridge. He writes mainly in the areas of metaethics, normative ethics, legal philosophy, and political philosophy; Director of the Cambridge Forum for Legal and Political Philosophy; elected a Fellow of the British Academy, the United Kingdom's national academy for the humanities and social sciences. Arthur Koestler, novelist and critic Bernard Kops, poet Peter Kosminsky (born 21 April 1956) is a British writer, director, screenwriter and producer; has directed Hollywood movies such as White Oleander and television films like Warriors, The Government Inspector, The Promise, Wolf Hall and The State. Elena Lappin is a writer and editor.
Sources: en.wikipedia.org
== Medical uses == For over 90 years, hematopoietic stem cell transplantation (HSCT) has been used to treat people with conditions such as leukemia and lymphoma; this is the only widely practiced form of stem-cell therapy. During chemotherapy, most growing cells are killed by the cytotoxic agents. These agents, however, cannot discriminate between the leukaemia or neoplastic cells, and the hematopoietic stem cells within the bone marrow. This is the side effect of conventional chemotherapy strategies that the stem-cell transplant attempts to reverse; a donor's healthy bone marrow reintroduces functional stem cells to replace the cells lost in the host's body during treatment. The transplanted cells also generate an immune response that helps to kill off the cancer cells; this process can go too far, however, leading to graft vs host disease, the most serious side effect of this treatment. Another stem-cell therapy called Prococvhymal, was conditionally approved in Canada in 2012 for the management of acute graft-vs-host disease in children who are unresponsive to steroids. It is an allogenic stem therapy based on mesenchymal stem cells (MSCs) derived from the bone marrow of adult donors. MSCs are purified from the marrow, cultured and packaged, with up to 10,000 doses derived from a single donor. The doses are stored frozen until needed. The FDA has approved five hematopoietic stem-cell products derived from umbilical cord blood, for the treatment of blood and immunological diseases.
Once a food source is suspected, traceback investigations trace it through the supply chain to pinpoint where contamination occurred. Findings are reported to the CDC's National Outbreak Reporting System (NORS). In the United States, PulseNet, a national laboratory network established in 1996, uses whole genome sequencing (WGS) of bacterial isolates to link cases across jurisdictions that might otherwise appear unrelated. Prior to WGS, pulsed-field gel electrophoresis (PFGE) served as the standard subtyping method for over two decades before being phased out in favor of the higher resolution offered by WGS.
60th Academy Awards: Best Supporting Actor, nomination, for Street Smart (1987) 62nd Academy Awards: Best Actor, nomination, for Driving Miss Daisy (1989) 67th Academy Awards: Best Actor, nomination, for The Shawshank Redemption (1994) 77th Academy Awards: Best Supporting Actor, win, for Million Dollar Baby (2004) 82nd Academy Awards: Best Actor, nomination, for Invictus (2009) Freeman has been nominated for five Golden Globe Awards, winning one for Best Actor in Driving Miss Daisy (1989). He has also been nominated for three Screen Actors Guild Awards, winning one for Outstanding Performance by a Male Actor in a Supporting Role in Million Dollar Baby (2004). He earned an Obie Award for each theater role in Coriolanus (1979), Mother Courage and Her Children (1980), and Driving Miss Daisy (1987–90).
==== Wound healing ==== High dose aspirin treatment (which inhibits cyclooxygenases-1 and -2 to block their production of 12-HHT), thromboxane synthase knockout, and BLT2 receptor knockout, but not TXA2 receptor knockout, impair keratinocyte-based re-epithelialization and thereby closure of experimentally induced wounds in mice. A synthetic BLT2 receptor agonist accelerates wound closure not only in this mouse model but also in the db/db mouse model of obesity, diabetes, and dyslipidemia due to leptin receptor deficiency. 12-HHT accumulated in the wounds of the former mouse model. Companion studies using an in vitro scratch test assay indicated that 12-HHT stimulated human and mouse keratinocyte migration by a BLT2 receptor-dependent mechanism that involved the production of tumor necrosis factor α and metalloproteinases. These results indicate that the 12-HHT/BLT2 receptor axis is a critical contributor to wound healing in mice and possibly humans. The axis operates by recruiting the movement of keratinocytes to close the wound. This mechanism may underlie the suppression of wound healing that accompanies the high dose intake of aspirin and, based on mouse studies, other non-steroidal anti-inflammatory agents (NSAIDs) in humans. Synthetic BLT2 agonists may be useful for speeding the healing of chronic ulcerative wounds, particularly in patients with, for example diabetics, that have impaired wound healing.
Sources: en.wikipedia.org
Research-grade SR9009 is typically stored frozen at about minus twenty degrees Celsius, protected from light and moisture. Stock solutions are often kept in aliquots to avoid repeated freeze-thaw cycles. Specific storage conditions should follow the supplier's documentation.
Liquid chromatography with tandem mass spectrometry is widely used to detect and confirm SR9009 in laboratory samples. The technique offers high sensitivity and can distinguish the target compound from related substances. Nuclear magnetic resonance and ultraviolet detection may support identity and purity checks.
Online products labeled as SR9009 may vary in identity, purity, and actual content. Independent testing helps confirm that a sample matches its label and does not contain unexpected contaminants. This is important for reproducible research and for interpreting experimental results.
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.